Translating Clinical Trials Into a Real-World Setting: Addressing Issues With Adherence in Asthma
Professor Liam Heaney
Queens University, Belfast, Ireland
Lack of medication adherence is a widespread issue, costing the U.S. health care system $100 billion to $289 billion annually, and the European Union health care system €125 billion each year. Long-term adherence, such as that required by chronic conditions like asthma, is particularly challenging for patients. Non-adherence in late stage asthma trials is a significant challenge for drug developers. Rates of adherence across studies can vary widely, making it difficult to generalize clinical results of asthma trials into a real-world setting. This results in uncertainty among pharmaceutical companies, regulators, prescribers, payors and patients.
In a new white paper, Translating Clinical Trials Into a Real-World Setting: Addressing Issues With Adherence in Asthma, PPD’s experts address key topics that include:
- Regulatory implications of poor adherence
- Real-world measurement approaches
- Best practices for improving adherence in clinical trials
- Future measurement trends in real-world settings
Understanding the regulatory, measurement and adherence issues associated with late stage asthma trials and having a plan to proactively address them is vital for success. Download PPD’s latest white paper to learn how to overcome potential risks to ensure your asthma product reaches its full commercial potential.